|
|
Article: Baxter Healthcare Corp. Hyland Division announced a third indication for Gammagard IGIV for treatment of CLL patients. (B-cell Chronic Lymphocytic Leukemia)
- Article from:
- PR Newswire
- Article date:
- May 18, 1989
CopyrightCOPYRIGHT 1989 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BAXTER HEALTHCARE CORP. HYLAND DIVISION ANNOUNCED A THIRD INDICATION
FOR GAMMAGARD IGIV FOR TREATMENT OF CLL PATIENTS
GLENDALE, Calif., May 18 /PRNewswire/ -- Baxter Healthcare Corp. today announced the approval of a third indication of their Gammagard Immune Globulin Intravenous (Human)(IGIV), for the prevention of bacterial infection in patients with B-cell Chronic Lymphocytic Leukemia (CLL).
This approval follows the October 1988 completion of clinical trials entitled, "Intravenous Immune Globulin for the Prevention of Infection in Chronic Lymphocytic Leukemia." The multicenter, double-blind study, conducted by a cooperative ...